A Randomised Controlled Trial to Evaluate the Efficacy of Pradarari Churna and Pushyanuga Churna in the Management of Asrigdara (Dysfunctional Uterine Bleeding)

Introduction: Asrigdara, correlated with Dysfunctional Uterine Bleeding (DUB), is a common gynaecological disorder characterised by abnormal uterine bleeding without detectable pathology. This study aimed to clinically evaluate and compare the efficacy of Pradarari Churna and Pushyanuga Churna in their management. Materials and Methods: 40 patients diagnosed with Asrigdara (DUB) were randomly divided into two groups of 20 each. Group A received Pradarari Churna (500 mg BD) with Sitajala, and Group B received Pushyanuga Churna (500 mg BD) with Tandulodaka and Madhu for two months. Results: Both groups showed significant improvement in all clinical parameters (p<0.001). Overall symptomatic relief was 61.48% in Group A and 66.17% in Group B. Conclusion: Both formulations are safe and effective. Pradarari Churna showed comparable efficacy to the classical Pushyanuga Churna in addressing symptoms and underlying doshic imbalances.